Currently there are no approved pharmacologicaltreatments for non-alcoholic fatty liver disease(NAFLD), including the subtype non-alcoholicsteatohepatitis (NASH). The prevalence of thedisease is on the rise, as are common comorbiditiessuch as diabetes, insulin resistance and obesitythat contribute to this disease. NAFLD is a leadingcause of liver disease and can potentially result inhepatocellular carcinoma (HCC).
Over the past fewyears there has been increased interest from ourTrialtrove clients for clinical trials intelligence on thetreatment of (NAFLD), including the subtype (NASH).In the following report, I will leverage Trialtrovedata to assess the current industry sponsored trialslandscape, including patient demographics, triallocations and which pharmaceutical companies arebest positioned to enter the NAFLD market.
As of February 2017, Trialtrove has captured 594 trials for symptom relief and/or the treatment, modification, or cure of NAFLD.
Download the Whitepaper to find out more about the trials now
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: